Subcutaneous semaglutide: Phase IIIa data

Top-line data from the double-blind, international Phase IIIa SUSTAIN 6 trial in about 3,300 Type II diabetics showed that once-weekly subcutaneous semaglutide plus standard of care (SOC) met the prim...